Aurobindo Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Aurobindo Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1264, down 2.58% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.7% on the day, quoting at 23540.9. The Sensex is at 77652.44, down 0.7%.Aurobindo Pharma Ltd has added around 1.98% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has increased around 2.94% in last one month and is currently quoting at 23228.55, down 1.14% on the day. The volume in the stock stood at 3.15 lakh shares today, compared to the daily average of 11.01 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 1270.9, down 2.59% on the day. Aurobindo Pharma Ltd jumped 12.9% in last one year as compared to a 9.26% rally in NIFTY and a 32.39% spurt in the Nifty Pharma index.

The PE of the stock is 36.71 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1336.4, up 2.93% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.2% on the day, quoting at 23596.55078125. The Sensex is at 77995.46, down 0.32%. Aurobindo Pharma Ltd has gained around 6.51% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 4.45% in last one month and is currently quoting at 23241.15, up 0.9% on the day. The volume in the stock stood at 17.27 lakh shares today, compared to the daily average of 10.78 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 1344, up 2.67% on the day. Aurobindo Pharma Ltd is up 23.72% in last one year as compared to a 8.53% jump in NIFTY and a 39.09% jump in the Nifty Pharma index.

The PE of the stock is 36.83 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma, announced that it has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version.

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.

Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer.

Powered by Capital Market - Live News

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for intravenous infusion.

Bevacizumab is used in the treatment of various cancers, including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The pharma major reported a 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24.

Shares of Aurobindo Pharma fell 1.17% to close at Rs 1,240.70 on Friday, 20 December 2024.

Powered by Capital Market - Live News